Foghorn Therapeutics Inc. (FHTX) Financial Ratios
8 years of historical data (2018–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 1.38
30Y Low1.4·High1.4
P/B Ratio
↑
N/A
—
5yr avg: 1188.94
30Y Low5.1·High8.8
ROE
↓
N/A
—
5yr avg: -154.0%
30Y Low-237%·High-83%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
FHTX Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Foghorn Therapeutics Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $252M | $340M | $259M | $271M | $265M | $850M | $746M | — | — |
| Enterprise Value | $212M | $300M | $241M | $235M | $265M | $807M | $735M | — | — |
| P/E Ratio → | -3.76 | — | — | — | — | — | — | — | — |
| P/S Ratio | 8.14 | 11.00 | 11.46 | 7.93 | 13.80 | 644.51 | 1734.31 | — | — |
| P/B Ratio | — | — | — | — | 2369.11 | 8.78 | 5.10 | — | — |
| P/FCF | — | — | — | — | 1.38 | — | — | — | — |
| P/OCF | — | — | — | — | 1.37 | — | — | — | — |
P/E links to full P/E history page with 30-year chart
FHTX EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 9.72 | 10.65 | 6.89 | 13.76 | 612.05 | 1709.19 | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | 1.38 | — | — | — | — |
FHTX Profitability
Margins and return-on-capital ratios measuring operating efficiency
Foghorn Therapeutics Inc. earns an operating margin of -265.6%. Operating margins have expanded from -315.9% to -265.6% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.2% | 89.2% | 100.0% | 100.0% | 100.0% | 100.0% | -13322.1% | — | — |
| Operating Margin | -265.6% | -265.6% | -454.3% | -315.9% | -609.2% | -7637.1% | -15937.4% | — | — |
| Net Profit Margin | -240.3% | -240.3% | -383.2% | -288.2% | -566.3% | -7681.6% | -16000.0% | — | — |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | -224.5% | -83.4% | -236.5% | — | — |
| ROA | -30.8% | -30.8% | -30.4% | -28.5% | -23.6% | -26.1% | -49.5% | -156.4% | -61.2% |
| ROIC | — | — | — | — | -328.6% | -79.8% | -209.7% | — | — |
| ROCE | -46.2% | -46.2% | -46.2% | -37.4% | -28.5% | -28.5% | -55.6% | -207.3% | -65.8% |
FHTX Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $81M exceeds total debt of $41M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 459.88 | 0.60 | 0.56 | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -6.31 | -0.44 | -0.07 | — | — |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | -0.00 | — | — | — | — |
| Interest Coverage | — | — | — | — | — | -52.85 | -70.00 | -94.60 | -70.21 |
Net cash position: cash ($81M) exceeds total debt ($41M)
FHTX Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Foghorn Therapeutics Inc.'s current ratio of 2.73x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has declined from 4.11x to 2.73x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.73 | 2.73 | 3.73 | 4.11 | 6.37 | 9.44 | 10.12 | 1.33 | 11.68 |
| Quick Ratio | 2.73 | 2.73 | 3.73 | 4.11 | 6.37 | 9.44 | 10.12 | 1.33 | 11.68 |
| Cash Ratio | 2.66 | 2.66 | 3.64 | 4.01 | 6.26 | 3.17 | 9.86 | 1.18 | 11.57 |
| Asset Turnover | — | 0.16 | 0.08 | 0.12 | 0.05 | 0.00 | 0.00 | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | — | — | — | — | 83017.44 | — | — | — |
FHTX Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Foghorn Therapeutics Inc. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | 72.5% | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $63M | $55M | $42M | $42M | $37M | $37M | $37M | $20M |
Peer Comparison
Compare FHTX with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 FHTXYou | $252M | -3.8 | — | — | 89.2% | -265.6% | — | — | — |
 RVMD | $30B | -23.8 | — | — | — | — | -58.1% | -54.3% | — |
 TNGX | $3B | -26.5 | — | — | 96.3% | -178.4% | -37.2% | -38.5% | — |
 VYNE | $28M | -1.1 | — | — | 96.0% | -5219.1% | -66.3% | -124.0% | — |
 PRAX | $10B | -24.5 | — | — | — | — | -45.8% | -65.0% | — |
 AUPH | $2B | 7.4 | 19.2 | 14.9 | 88.5% | 37.1% | 59.9% | 16.6% | 0.7 |
 KYMR | $7B | -23.3 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 ARQT | $3B | -162.8 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 IMVT | $6B | -10.6 | — | — | — | — | -62.5% | — | — |
 PMVP | $75M | -1.0 | — | — | — | — | -55.4% | -63.4% | — |
 STRO | $342M | -1.4 | — | — | 88.4% | -384.3% | -234.2% | — | — |
| Healthcare Median | — | 21.9 | 14.2 | 18.5 | 64.3% | -5.0% | -34.0% | -11.0% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See FHTX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs FHTX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare FHTX vs RVMD
Side-by-side business, growth, and profitability comparison vs Revolution Medicines, Inc..
Start ComparisonFHTX — Frequently Asked Questions
Quick answers to the most common questions about buying FHTX stock.
What is Foghorn Therapeutics Inc.'s P/E ratio?
Foghorn Therapeutics Inc.'s current P/E ratio is -3.8x. This places it at the 50th percentile of its historical range.
Is FHTX stock overvalued?
Based on historical data, Foghorn Therapeutics Inc. is trading at a P/E of -3.8x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Foghorn Therapeutics Inc.'s profit margins?
Foghorn Therapeutics Inc. has 89.2% gross margin and -265.6% operating margin.